Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.45 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.45 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.45 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | PRKCG | P05129 | 1/20 | 0.44 |
| ▸ | PRKCB | P05771 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | PRKACG | P22612 | 1/20 | 0.44 |
| ▸ | PRKACB | P22694 | 1/20 | 0.44 |
| ▸ | PRKCH | P24723 | 1/20 | 0.44 |
| ▸ | PRKCI | P41743 | 1/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.44 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.44 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30637639 | 1.00 | NPC1 (0.46) | NPC1HSP90AA1TRAP1HSP90AB1HSP90B1 | |
| SCHEMBL30928942 | 1.00 | NPC1 (0.46) | NPC1HSP90AA1TRAP1HSP90AB1HSP90B1 | |
| SCHEMBL28436731 | 0.85 | L3MBTL1 (0.56) | HSP90AA1TRAP1HSP90AB1HSP90B1PRKD3 | |
| SCHEMBL15055383 | 0.83 | PLAU (0.43) | HSP90AA1TRAP1HSP90AB1HSP90B1LMNA | |
| SCHEMBL154462 | 0.83 | NOTUM (0.50) | HSP90AA1TRAP1HSP90AB1HSP90B1LMNA | |
| SCHEMBL7854463 | 0.83 | PARP1 (0.41) | HSP90AA1TRAP1HSP90AB1HSP90B1LMNA | |
| SCHEMBL31125883 | 0.82 | MAPT (0.48) | KDM4EMAPTCDC7CDK2 | |
| SCHEMBL27747424 | 0.82 | CA12 (0.47) | NPC1HSP90AA1TRAP1HSP90AB1HSP90B1 | |
| SCHEMBL6840290 | 0.81 | RXRA (0.49) | NPC1LMNAKDM4EGAAALDH1A1 | |
| SCHEMBL152899 | 0.81 | HSP90AA1 (0.50) | HSP90AA1TRAP1HSP90AB1HSP90B1PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0931065-A2 | NITRIC ESTER DERIVATIVES AND THEIR USE IN URINARY INCONTINENCE AND OTHER DISEASES | NICOX S.A. (FR) | 1999-07-28 | — | — | EP | claimed |
| WO-1998009948-A2 | NITRIC ESTER DERIVATIVES AND THEIR USE IN URINARY INCONTINENCE AND OTHER DISEASES | NICOX S.A. (FR) | 1998-03-12 | — | — | WO | claimed |
| US-10730856-B2 | Benzimidazole derivatives as EP4 ligands | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-08-04 | — | — | US | disclosed |
| WO-2019038156-A1 | USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-28 | — | — | WO | disclosed |
| WO-2018162562-A1 | USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF INFLAMMATORY PAIN | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-09-13 | — | — | WO | disclosed |
| US-9708311-B2 | Benzimidazole derivatives as EP4 antagonists | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-07-18 | — | — | US | disclosed |
| CN-104379579-B | Pyrrolidin derivatives and its purposes as complement pathway regulator | 诺华股份有限公司 | 2017-03-08 | — | — | CN | disclosed |
| US-20160318905-A1 | Novel benzimidazole derivatives as EP4 ligands | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-11-03 | — | — | US | disclosed |
| US-20160214977-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | BAYER ANIMAL HEALTH GMBH (DE) | 2016-07-28 | — | — | US | disclosed |
| CN-105188663-A | Topical aqueous ophthalmic compositions containing a 1H-indole-1-carboxamide derivative and use thereof for treatment of ophthalmic disease | NOVARTIS AG | 2015-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214977-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AS EP4 ANTAGONISTS | PTGER4, PTGER1, PTGER2 | NPC1 1969/4885HSP90AA1 2165/4885TRAP1 4001/4885 |
| US-20160318905-A1 | Novel benzimidazole derivatives as EP4 ligands | PTGER4, PTGER1, EPB41 | NPC1 1558/4885HSP90AA1 2075/4885TRAP1 3850/4885 |
| US-10730856-B2 | Benzimidazole derivatives as EP4 ligands | PTGER4, PTGER1, PTGER2 | NPC1 1816/4885HSP90AA1 2306/4885TRAP1 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.